Table 4 Clinician decision to pursue intradermal skin test versus oral challenge compared to risk stratification via penicillin de-labeling tool
Intradermal Skin Test (n, %) | Oral challenge (n, %) | Total (n, %) | ||
|---|---|---|---|---|
PENFAST | ≥ 3 | 6 (3.3%) | 15 (8.3%) | 21 (11.6%) |
0–2 | 14 (7.7%) | 146 (80.7%) | 160 (88.4%) | |
JAMA | High – medium | 17 (9.4%) | 55 (30.4%) | 72 (39.8%) |
Low | 3 (1.7%) | 106 (58.6%) | 109 (60.2%) | |
FIRSTLINE | High – possible | 13 (7.2%) | 11 (6.1%) | 24 (13.3%) |
Very low | 7 (3.9%) | 150 (82.9%) | 157 (86.7%) |